Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL

被引:34
|
作者
Sokoloff, MH
Yang, XJ
Fumo, M
Mhoon, D
Brendler, CB
机构
[1] Univ Chicago, Urol Sect, Dept Surg, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[3] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
关键词
prostate cancer; clinically significant; PSA; prostatectomy; immunohistochemistry;
D O I
10.1111/j.1464-410X.2003.04657.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To characterize prostate cancer in men undergoing radical prostatectomy who have a prostate-specific antigen (PSA) level of < 4.0 ng/mL, hypothesising that a low PSA is not caused by diminished tumour production of PSA, nor does it signify clinically insignificant disease. Seventy-nine men (mean age 59.3 years, range 43-77) with a PSA level of < 4.0 ng/mL were identified from 702 who had a radical prostatectomy between 1994 and 2000. Demographic and clinical data were analysed; pathological specimens were evaluated by routine haematoxylin and eosin staining and immunohistochemistry with anti-PSA antibody, for both pathological staging and grading, and for the presence of PSA production. Tumours were classified as 'clinically insignificant' if the tumour volume was < 0.5 mL and the Gleason score < 7. The mean (SD, range) preoperative PSA level was 3.04 (0.85, 0.8-3.8) ng/mL. Indications for biopsy included an abnormal digital rectal examination (61%), a PSA velocity of >0.75 ng/mL/year (12%), a strong family history of prostate cancer (3%), obstructive urinary symptoms (2%), or no obvious indication (23%). Thirty-eight (48%) tumours were clinically insignificant. Of 41 clinically significant cancers, 13 had a final Gleason score of greater than or equal to 7, 20 had extraprostatic extension and 11 had a tumour volume of greater than or equal to 10 mL. Of the 79 prostate cancer specimens 78 stained strongly for PSA; the exception was a Gleason 9 tumour. With a mean (range) follow-up of 3.5 (0.18-6) years only one patient had a biochemical recurrence (PSA greater than or equal to 0.1 ng/mL). Most prostate cancers in men with a PSA level of < 4.0 ng/mL are clinically significant and PSA-producing. Many of these tumours are high-grade, high-volume and extraprostatic. We are currently exploring factors to explain why serum PSA is not elevated in these men, including tumour location, pattern of invasion and microvessel density.
引用
下载
收藏
页码:499 / 502
页数:4
相关论文
共 50 条
  • [1] Serum free prostate specific antigen as a predictor of prostate volume in men with biopsy confirmed Benign Prostatic Hyperplasia and serum total prostate specific antigen &lt; 10ng/ml
    Basillote, JB
    Rivera, AD
    Pareek, G
    Hochberg, DA
    Armenakas, NA
    Fracchia, JA
    JOURNAL OF UROLOGY, 2002, 167 (04): : 272 - 272
  • [2] Serum Dehydroepiandrosterone Sulfate Usage for Early Detection of Prostate Cancer in Men with Serum Prostate Specific Antigen Level between 2.5 and 4.0 ng/ml: A Pilot Study
    Aslan, Yilmaz
    Tekdogan, Uemit
    Tuncel, Altug
    Uzun, Metin Burcin
    Karabulut, Erdem
    Atan, Ali
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2008, 38 (05) : 399 - 404
  • [4] Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL)
    Chung, Jae Hoon
    Yu, Jiwoong
    Song, Wan
    Kang, Minyong
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Lee, Hyun Moo
    Jeon, Seong Soo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (41)
  • [5] Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml.
    Okihara, K
    Fritsche, HA
    Ayala, A
    Johnston, DA
    Allard, WJ
    Babaian, RJ
    JOURNAL OF UROLOGY, 2001, 165 (06): : 1930 - 1936
  • [6] Significance of suspicious lesions at transrectal ultrasonography in men with serum prostate-specific antigen levels of &lt;20 ng/ml
    Shim, Hong Bang
    Lee, Sang Eun
    Park, Hyoung Keun
    Ku, Ja Hyeon
    TUMORI JOURNAL, 2007, 93 (02): : 178 - 181
  • [7] Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng/ml or less
    Harris, CH
    Dalkin, BL
    Martin, E
    Marx, PC
    Ahmann, FR
    JOURNAL OF UROLOGY, 1997, 157 (05): : 1740 - 1743
  • [8] Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml
    Khan, MA
    Partin, AW
    Rittenhouse, HG
    Mikolajczyk, SD
    Sokoll, LJ
    Chan, DW
    Veltri, RW
    JOURNAL OF UROLOGY, 2003, 170 (03): : 723 - 726
  • [9] A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen &lt; 10 ng/mL
    Miyoshi, Yasuhide
    Kawahara, Takashi
    Uemura, Hiroji
    BMC CANCER, 2022, 22 (01)
  • [10] Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL
    Okegawa, T
    Kinjo, M
    Ohta, M
    Miura, I
    Horie, S
    Nutahara, K
    Higashihara, E
    INTERNATIONAL JOURNAL OF UROLOGY, 2003, 10 (04) : 201 - 206